Phase II study of cilengitide in the treatment of refractory or relapsed high-grade gliomas in children: a report from the Children's Oncology Group.

Abstract

BACKGROUND:

Cilengitide, an αv integrin antagonist, has demonstrated activity in recurrent adult glioblastoma (GBM). The Children's Oncology Group ACNS0621 study thus evaluated whether cilengitide is active as a single agent in the treatment of children with refractory high-grade glioma (HGG). Secondary objectives were to investigate the pharmacokinetics and pharmacogenomics of cilengitide in this population.

METHODS:

Cilengitide (1800 mg/m(2)/dose intravenous) was administered twice weekly until evidence of disease progression or unacceptable toxicity. Thirty patients (age range, 1.1-20.3 years) were enrolled, of whom 24 were evaluable for the primary response end point.

RESULTS:

Toxicity was infrequent and mild, with the exception of one episode of grade 2 pain possibly related to cilengitide. Two intratumoral hemorrhages were reported, but only one (grade 2) was deemed to be possibly related to cilengitide and was in the context of disease progression. One patient with GBM received cilengitide for 20 months and remains alive with continuous stable disease. There were no other responders, with median time to tumor progression of 28 days (range, 11-114 days). Twenty-one of the 24 evaluable patients died, with a median time from enrollment to death of 172 days (range, 28-325 days). The 3 patients alive at the time of this report had a follow-up time of 37, 223, and 1068 days, respectively.

CONCLUSIONS:

We conclude that cilengitide is not effective as a single agent for refractory pediatric HGG. However, further study evaluating combination therapy with cilengitide is warranted before a role for cilengitide in the treatment of pediatric HGG can be excluded.

• Authors: Tobey J MacDonald, Gilbert Vezina, Clinton F Stewart, David Turner, Christopher R Pierson, Lu Chen, Ian F Pollack, Amar Gajjar, Mark W Kieran
• Journal: Neuro-oncology (Neuro Oncol) Vol. 15 Issue 10 Pg. 1438-44 (Oct 2013) ISSN: 1523-5866 [Electronic] England
• PMID: 24014381 (Publication Type: Clinical Trial, Phase II, Journal Article, Research Support, N.I.H., Extramural)

Chemical References

• Snake Venoms
• Cilengitide

Topics

• Adolescent
• Adult
• Brain Neoplasms (drug therapy, pathology)
• Child
• Child, Preschool
• Drug Resistance, Neoplasm (drug effects)
• Female
• Follow-Up Studies
• Glioma (drug therapy, pathology)
• Humans
• Infant
• Male
• Neoplasm Grading
• Neoplasm Recurrence, Local (drug therapy, pathology)
• Prognosis
• Salvage Therapy
• Snake Venoms (pharmacokinetics, therapeutic use)
• Survival Rate
• Tissue Distribution
• Young Adult